Market and facilitate the use of an infused biologic orphan drug indicated for the treatment of severe refractory gouty arthritis. Continuous education to prescribers on patient selection and counseling, working with billing staff (Buy and Bill) to facilitate patient access and pull through. Responsible for in-servicing infusion staff, identifying alternative sites of care, and strengthening referral networks between rheumatology, podiatry, nephrology and internal medicine.

Responsible for select portfolio in the federal government space. This includes military treatment facilities, VA hospitals and health care centers as well as Indian Health centers.

Launched and promoted Praluent. The first PCSK9 inhibitor approved in the US. Call points are cardiology, endocrinology and lipidology.

Worked in ‘ultra rare disease state’ marketing Juxtapid to clinicians treating patients with HoFH (Homozygous Familial Hypercholesterolemia). Juxtapid is indicated as an adjunct to a low-fat diet and other lipid lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein, cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (Apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia.Cover NC, east and west calling on Cardiology, Endocrinology, Internal Medicine and Family Practice.

Worked in Orphan disease state and marketed products to treat patients with PAH. Patients with Pulmonary Arterial Hypertension suffer from symptoms that are frequently confused with other ailments and often go misdiagnosed or not diagnosed at all. I have been able to culminate all of my experience in Cardiology, Pulmonology and Critical care to educate clinicians and hospitals on PAH. Driving referrals into the centers that treat with our products. Tyvaso, an inhaled prostacylcin and Remodulin SC or IV for patients that have more progressed disease.

Marketed Brevibloc premixed for injection. Calling on key accounts in NC including Duke, UNC, Wake Forest Baptist, Pitt etc. Brevibloc is used in various critical care unts as well as Emergency Departments. Brevibloc is an IV beta blocker that allows the medical professional to reach hemodynamic stability quickly and accurately. My hospital contacts include but are not limited to Cardiologists, Electrophysiologists, Intensivists, Emergency Medicine physicians and nursing professionals. Sales force was dissolved for this division.

Responsible for launch of new Direct Thrombin Inhibitor Pradaxa to hospitals in NC region. Work with KOL's to introduce to the cardiology, neurology and electrophysiology market as a viable option in preventing stroke and systemic embolism in patients with Afib.

Promotion of Precedex to all critical care areas of hospitals in NC including Duke, UNC. WFUBMC. Precedex is a drug marketed for sedation in the OR and ICU's. I also represented and marketed Voluven, a plasma volume expander.

Launched and marketed new anticoagulant (Angiomax) the NC marketplace. Calling primarily on cardiac cath labs and the invasive cardiology market.